» Articles » PMID: 36348054

Validation and Meaningful Change Thresholds for an Objective Cough Frequency Measurement in Chronic Cough

Overview
Journal Lung
Specialty Pulmonary Medicine
Date 2022 Nov 8
PMID 36348054
Authors
Affiliations
Soon will be listed here.
Abstract

Purpose: Objective cough frequency is used to assess efficacy of chronic cough (CC) treatments. The objective of this study was to explore the relationship between objective cough frequency and cough-specific patient-reported outcomes (PROs) and estimate a clinically meaningful change threshold (MCT) for objective cough frequency.

Methods: Data collected in a phase 2b study in participants with refractory or unexplained CC were used to investigate the relationship between 24-h cough frequency (measured using an ambulatory cough monitor) and cough-specific PROs (i.e., cough severity visual analog scale, cough severity diary, Leicester Cough Questionnaire). Convergent validity was assessed using Spearman ρ. An MCT for 24-h cough frequency was estimated using the patient global impression of change (PGIC) scale as an anchor.

Results: Correlations between 24-h cough frequency and cough-specific PROs at baseline, Week 4, and Week 12 were significant (P < 0.0001) but low to moderate in strength (ρ = 0.30-0.58). Participants categorized as very much improved/much improved (i.e., PGIC of 1 or 2) or minimally improved (i.e., PGIC of 3) had mean 24-h cough frequency reductions of 55% and 30%, respectively. Receiver operating characteristic curve analysis suggested that a 24-h cough frequency reduction of 38% optimizes sensitivity and specificity for predicting a PGIC score of 1-3.

Conclusion: Objective 24-h cough frequency is significantly associated with cough-specific PROs, but cough frequency and PROs most likely capture distinct aspects of CC. A ≥ 30% reduction in 24-h cough frequency is a reasonable MCT to define treatment response in CC clinical trials.

Citing Articles

Patient-reported assessments of chronic cough in clinical trials: accessory or primary endpoints?.

Mackay E, Turner R, Cho P, Birring S J Thorac Dis. 2024; 16(10):7165-7181.

PMID: 39552840 PMC: 11565313. DOI: 10.21037/jtd-24-705.


Prevalence of refractory and unexplained chronic cough in adults treated in cough centre.

Kukielka P, Moliszewska K, Bialek-Gosk K, Grabczak E, Dabrowska M ERJ Open Res. 2024; 10(5).

PMID: 39319047 PMC: 11417602. DOI: 10.1183/23120541.00254-2024.


An accelerometry and gyroscopy-based system for detecting swallowing and coughing events.

Stevens G, van de Velde S, Larmuseau M, Poelaert J, Van Damme A, Verdonck P J Clin Monit Comput. 2024; 39(1):157-167.

PMID: 39305451 DOI: 10.1007/s10877-024-01222-6.


Patient-reported experiences with refractory or unexplained chronic cough: a qualitative analysis.

Bali V, Schelfhout J, Sher M, Tripathi Peters A, Patel G, Mayorga M Ther Adv Respir Dis. 2024; 18:17534666241236025.

PMID: 38501735 PMC: 10953008. DOI: 10.1177/17534666241236025.


The Therapeutic Landscape in Chronic Cough.

Smith J Lung. 2023; 202(1):5-16.

PMID: 38127133 PMC: 10896934. DOI: 10.1007/s00408-023-00666-y.


References
1.
Birring S, Wijsenbeek M, Agrawal S, van den Berg J, Stone H, Maher T . A novel formulation of inhaled sodium cromoglicate (PA101) in idiopathic pulmonary fibrosis and chronic cough: a randomised, double-blind, proof-of-concept, phase 2 trial. Lancet Respir Med. 2017; 5(10):806-815. DOI: 10.1016/S2213-2600(17)30310-7. View

2.
Smith J, Holt K, Dockry R, Sen S, Sheppard K, Turner P . Performance of a digital signal processing algorithm for the accurate quantification of cough frequency. Eur Respir J. 2021; 58(2). DOI: 10.1183/13993003.04271-2020. View

3.
McGarvey L, Gibson P . What Is Chronic Cough? Terminology. J Allergy Clin Immunol Pract. 2019; 7(6):1711-1714. DOI: 10.1016/j.jaip.2019.04.012. View

4.
Kelsall A, Decalmer S, Webster D, Brown N, McGuinness K, Woodcock A . How to quantify coughing: correlations with quality of life in chronic cough. Eur Respir J. 2008; 32(1):175-9. DOI: 10.1183/09031936.00101307. View

5.
Morice A, Birring S, Smith J, McGarvey L, Schelfhout J, Nguyen A . Characterization of Patients With Refractory or Unexplained Chronic Cough Participating in a Phase 2 Clinical Trial of the P2X3-Receptor Antagonist Gefapixant. Lung. 2021; 199(2):121-129. PMC: 8053171. DOI: 10.1007/s00408-021-00437-7. View